Tarsus Pharmaceuticals, Inc. (TARS) Dividend History

Company News

• Tarsus to Participate in Upcoming Investor Conferences

  Tarsus Pharmaceuticals announced plans to participate in several upcoming investor conferences, including the William Blair 45th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 46th Annual Global Healthcare Conference.

  GlobeNewswire Inc.
• Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

  Elanco Animal Health has sold certain future royalties and commercial milestones associated with its Xdemvy product to Blackstone for $295 million. The company will use the proceeds to reduce its debt and expects to achieve a net leverage ratio of 3.9x-4.3x EBITDA by the end of 2025.

  Benzinga

  Featured Companies: ELAN
• Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

  Tarsus Pharmaceuticals, Inc. (TARS) will host a webcast to report its Q1 2025 financial results and provide a corporate update. The company is also presenting data on the global prevalence and patient burden of Demodex blepharitis at the ASCRS 2025 Annual Meeting.

  GlobeNewswire Inc.
• Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

  Tarsus Pharmaceuticals announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share, with the gross proceeds expected to be approximately $125.0 million.

  GlobeNewswire Inc.
• Tarsus to Participate in Upcoming Investor Conference

  Tarsus Pharmaceuticals, Inc. announced that it will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 11th. The company is advancing its pipeline, including FDA-approved XDEMVY® for the treatment of Demodex blepharitis and TP-04 and TP-05 for the potential treatment of Ocular Rosacea and prevention of Lyme disease, respectively.

  GlobeNewswire Inc.